Treatment Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Chronic Myelomonocytic Leukemia

CMML is a diagnosis typically made after age 70 years. The clinical course of CMML ranges from indolent or smoldering disease to an aggressive disease progression culminating in severe cytopenias or evolution to acute leukemia. Assessment of the risk factors and the pace of disease over time may help to distinguish patients who require therapy from those who would be best managed with a watchful waiting approach. Asymptomatic patients at low risk of progression may be best served by forgoing therapy.[19,20]

Source links and citations

Continue within this section

Allogeneic stem cell transplant (SCT) →Hypomethylating agents →Hydroxyurea →Hypomethylating agent versus hydroxyurea →Other regimens →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice